Tangen Biosciences Financing
Tangen Biosciences, Inc., Corporation just submitted form D because of $8.00 million equity financing. This is a new filing. Tangen Biosciences, Inc. is expected to finance itself with $8.00 million in this fundraising offer. The total private offering amount was $8.00 million. This form was filed on 2016-11-02. The reason for the financing was: unspecified. The fundraising still has about $8.00 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Tangen Biosciences is based in Connecticut. The firm’s business is Biotechnology. The form was signed by John Nobile Director. The company was incorporated in 2013. The filler’s address is: 780 East Main St., Suite 1, Branford, Ct, Connecticut, 06405. John Nobile is the related person in the form and it has address: 780 E Main Street, Suite 1, Branford, Ct, Connecticut, 06405. Link to Tangen Biosciences Filing: 000166195516000001.
Analysis of Tangen Biosciences Offering
On average, startups in the Biotechnology sector, sell 73.77% of the total offering amount. Tangen Biosciences sold 0.00% of the offering. The fundraising is still open. The average offering amount for companies in the Biotechnology industry is $3.08 million. The offering was 100.00% smaller than the average of $3.08 million. Of course this should not be interpreted as negative. Startups get financed for different needs and reasons. The minimum investment for this fundraising is set at $250000. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Tangen Biosciences Also
The Form D signed by John Nobile might help Tangen Biosciences, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.